PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)

This study is testing whether adding an immunotherapy drug (a PD-1 inhibitor) to standard chemotherapy and radiation therapy before surgery can improve outcomes for people with locally advanced squamous cell cancer of the esophagus. **You may be eligible if...** - You have been diagnosed with squamous cell esophageal cancer that is potentially removable by surgery, at a specific stage (T1–4a with lymph node involvement, or T3–4a without) - You are between 18 and 70 years old - You have not received any prior cancer treatments - Your blood counts and organ function are within acceptable ranges - Your general health score (performance status) is 0 or 1 - Your expected survival is more than 6 months **You may NOT be eligible if...** - You have already received chemotherapy, radiation, or immunotherapy - You have distant cancer spread (metastatic disease) - Your blood counts or organ function are below required levels - You are unable to tolerate combined chemoradiation Talk to your doctor to see if this trial is right for you.